What's Happening?
bioAffinity Technologies, a biotechnology company focused on noninvasive diagnostics, has reported a significant increase in sales for its CyPath® Lung diagnostic test. In April 2026, the company achieved a record high in unit sales, marking a nearly
300% increase compared to the same period in 2025. This growth reflects a trend of accelerating adoption and clinical use of the test, which aids in diagnosing lung cancer. The CyPath® Lung test uses advanced flow cytometry and artificial intelligence to detect lung cancer in high-risk patients, offering a noninvasive alternative to traditional diagnostic methods. The test has demonstrated high sensitivity and specificity in clinical trials, providing physicians with greater confidence in negative results and potentially reducing the need for invasive procedures.
Why It's Important?
The significant growth in CyPath® Lung sales highlights the increasing demand for noninvasive diagnostic tools in the healthcare sector. This trend is particularly important for lung cancer detection, where early diagnosis can significantly improve treatment outcomes. The test's ability to accurately assess cancer risk and manage pulmonary nodules addresses a critical gap in the diagnostic pathway, offering a safer and more cost-effective alternative to invasive procedures. As the number of patients with indeterminate pulmonary nodules rises, driven by increased screening and incidental findings, the adoption of such noninvasive tests is likely to expand, potentially transforming lung cancer risk assessment and management practices.
What's Next?
bioAffinity Technologies plans to continue expanding the clinical impact of its CyPath® Lung test. The company is advancing initiatives such as a large-scale longitudinal clinical study to generate additional validation data and exploring broader applications for monitoring lung cancer survivors post-treatment. Additionally, bioAffinity is developing diagnostic tests for other respiratory conditions like asthma and COPD, aiming to guide personalized treatment with targeted therapies. These efforts are part of a focused commercial strategy to increase the adoption of CyPath® Lung and integrate it into clinical workflows for lung cancer risk assessment and nodule management.
